Yes. Off-label prescribing of ketamine by physicians is legal, and it occurs routinely in clinical practice.
The Food, Drug, and Cosmetic Act regulates the approval of pharmaceutical products for specific indications, but it does not restrict physicians from prescribing approved drugs for uses not included in the FDA-approved labeling. Once a drug is approved for any indication and available in the market, a physician may prescribe it for any condition that the physician’s clinical judgment supports, regardless of whether that condition is described in the drug’s approved labeling. This principle, the off-label prescribing doctrine, is one of the most fundamental features of the regulatory relationship between FDA approval and medical practice.
The Legal Basis for Off-Label Prescribing
The FDA has consistently maintained that the practice of medicine is outside its regulatory jurisdiction and that physicians may prescribe approved drugs off-label as a matter of their professional clinical judgment. The FDA’s regulatory authority extends to drug manufacturers, requiring them to market only for approved indications, but it does not extend to the physician’s prescribing decision. A manufacturer who promotes a drug for an off-label use violates the FD&C Act. A physician who prescribes the same drug for the same off-label use does not.
The DEA’s authority over ketamine prescribing does not alter this principle. The DEA’s requirement that controlled substance prescriptions be issued for a legitimate medical purpose within the usual course of professional practice is satisfied by an off-label prescribing decision that reflects genuine clinical judgment, is documented in the patient’s medical record, and is supported by a clinical rationale that the prescribing practitioner can articulate. The legitimate medical purpose standard does not require FDA approval of the specific indication; it requires that the use reflect a genuine therapeutic purpose rather than a commercial drug distribution purpose.
Ketamine’s Principal Off-Label Applications
Ketamine’s most clinically significant off-label applications in the current therapeutic landscape are its use for treatment-resistant depression, suicidal ideation, post-traumatic stress disorder, and chronic pain management. These applications have been studied extensively in the medical literature, are supported by an accumulating body of clinical evidence, and are practiced at an increasing number of specialized clinical facilities across the country.
Need Help With Your Case?
Don't face criminal charges alone. Our experienced defense attorneys are ready to fight for your rights and freedom.
- 100% Confidential
- Response Within 1 Hour
- No Obligation Consultation
Or call us directly:
(212) 300-5196The clinical evidence supporting these applications varies by indication. The evidence base for ketamine in treatment-resistant depression is among the strongest: multiple randomized controlled trials and meta-analyses have demonstrated rapid antidepressant effects in patients who have not responded to conventional antidepressant therapy. The evidence for other applications is at various stages of development, and the clinical practice for those applications reflects a combination of published evidence and clinical judgment that is characteristic of off-label prescribing in any area of medicine.
The Standard of Care for Off-Label Ketamine Prescribing
The standard of care for off-label ketamine prescribing is determined by the clinical guidelines, published evidence, and professional society standards applicable to the specific off-label use. For treatment-resistant depression, the American Psychiatric Association has published guidance on ketamine and esketamine treatment that describes the clinical circumstances in which ketamine therapy is appropriate and the protocols under which it should be administered. For chronic pain applications, the American Society of Regional Anesthesia and Pain Medicine has published consensus guidelines on the use of ketamine for chronic pain.
These guidelines are evidence of the standard of care that courts and regulatory bodies will apply to off-label ketamine prescribing. The practitioner who follows applicable guidelines, documents the clinical basis for the treatment decision, and administers ketamine within the protocols those guidelines describe has a strong basis for demonstrating that the prescribing was within the usual course of professional practice. The practitioner who prescribes outside those guidelines without documenting the clinical rationale for the deviation has created the same kind of compliance risk that undocumented deviation from any applicable standard creates.
Todd Spodek
Lead Attorney & Founder
Featured on Netflix's "Inventing Anna," Todd Spodek brings decades of high-stakes criminal defense experience. His aggressive approach has secured dismissals and acquittals in cases others deemed unwinnable.
Off-label ketamine prescribing is legal. It is also subject to the same usual course of professional practice standard that governs all controlled substance prescribing. The legality of the off-label use is not a defense to the allegation that the specific prescription was issued outside that standard. The defense is the clinical record that demonstrates the prescription was a genuine therapeutic decision for a specific patient whose condition warranted the treatment.
Federal agents execute a search warrant at your medical practice, seizing patient records and prescription logs.
Can they take patient records without patient consent?
A valid federal search warrant overrides HIPAA privacy protections. However, the warrant must be properly scoped. An attorney can challenge overly broad warrants and move to suppress improperly seized evidence.
This is general information only. Contact us for advice specific to your situation.
Documentation Requirements for Off-Label Prescribing
The clinical documentation standard for off-label ketamine prescribing should reflect the specific clinical rationale for choosing ketamine for the particular patient’s condition, the evidence or guidelines supporting the off-label use, the patient’s treatment history demonstrating failure of conventional treatments where applicable, the patient’s informed consent to off-label therapy, and the monitoring plan for assessing the treatment’s effectiveness and the patient’s safety during and after administration. Off-label prescribing that is undocumented, or documented only as a prescription without supporting clinical narrative, creates the same evidentiary vulnerability as any other controlled substance prescribing without adequate documentation.
